Lung involvement in hypereosinophilic syndromes

Megan Dulohery Scrodin, Rajesh R. Patel, Frank Schneider, Jay H Ryu

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Hypereosinophilic syndromes (HES) are a heterogeneous group of conditions that are characterized by tissue-associated eosinophilic inflammation and peripheral eosinophilia. Although clinical and radiologic features associated with most forms of eosinophilic lung diseases are relatively well-described, there is little known regarding lung involvement in HES. The aims of the present study were to ascertain the frequency of pulmonary involvement in HES and define associated clinical and radiologic features. Methods: We included all patients with HES seen over a 5-year period from 2004 to 2008 and examined their medical records and radiologic studies to obtain relevant data. Results: There were 49 patients (25 males and 24 females) with a median age of 50 years (range, 12-88 years); 18 (37%) had a history of tobacco use. In 12 patients (24%), these pulmonary manifestations were attributable to parenchymal lung involvement with HES. Radiologic manifestations of pulmonary involvement varied but most commonly consisted of patchy ground-glass opacities and consolidation; one patient exhibited numerous pulmonary nodules. Thirteen patients (27%) had asthma including 6 with a new diagnosis of this disorder. Initial treatment usually consisted of corticosteroids but additional therapeutic agents were employed during the clinical course and included hydroxyurea, interferon-α, imatinib, and mepolizumab. Most patients with pulmonary involvement with HES improved and no deaths were observed. Conclusion: One-quarter of HES patients manifested pulmonary involvement with variable radiologic findings. Asthma was more common in HES than previously reported. Most patients with pulmonary involvement in HES improve with currently available therapies.

Original languageEnglish (US)
Pages (from-to)114-121
Number of pages8
JournalRespiratory Medicine
Volume105
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Hypereosinophilic Syndrome
Lung
Asthma
Hydroxyurea
Eosinophilia
Tobacco Use
Interferons
Lung Diseases
Medical Records
Glass
Adrenal Cortex Hormones
Therapeutics
Inflammation

Keywords

  • Asthma
  • Eosinophilic lung disease
  • Interstitial lung disease

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Lung involvement in hypereosinophilic syndromes. / Dulohery Scrodin, Megan; Patel, Rajesh R.; Schneider, Frank; Ryu, Jay H.

In: Respiratory Medicine, Vol. 105, No. 1, 01.2011, p. 114-121.

Research output: Contribution to journalArticle

Dulohery Scrodin, Megan ; Patel, Rajesh R. ; Schneider, Frank ; Ryu, Jay H. / Lung involvement in hypereosinophilic syndromes. In: Respiratory Medicine. 2011 ; Vol. 105, No. 1. pp. 114-121.
@article{be1b4e9a47b349ffab0a720040537434,
title = "Lung involvement in hypereosinophilic syndromes",
abstract = "Background: Hypereosinophilic syndromes (HES) are a heterogeneous group of conditions that are characterized by tissue-associated eosinophilic inflammation and peripheral eosinophilia. Although clinical and radiologic features associated with most forms of eosinophilic lung diseases are relatively well-described, there is little known regarding lung involvement in HES. The aims of the present study were to ascertain the frequency of pulmonary involvement in HES and define associated clinical and radiologic features. Methods: We included all patients with HES seen over a 5-year period from 2004 to 2008 and examined their medical records and radiologic studies to obtain relevant data. Results: There were 49 patients (25 males and 24 females) with a median age of 50 years (range, 12-88 years); 18 (37{\%}) had a history of tobacco use. In 12 patients (24{\%}), these pulmonary manifestations were attributable to parenchymal lung involvement with HES. Radiologic manifestations of pulmonary involvement varied but most commonly consisted of patchy ground-glass opacities and consolidation; one patient exhibited numerous pulmonary nodules. Thirteen patients (27{\%}) had asthma including 6 with a new diagnosis of this disorder. Initial treatment usually consisted of corticosteroids but additional therapeutic agents were employed during the clinical course and included hydroxyurea, interferon-α, imatinib, and mepolizumab. Most patients with pulmonary involvement with HES improved and no deaths were observed. Conclusion: One-quarter of HES patients manifested pulmonary involvement with variable radiologic findings. Asthma was more common in HES than previously reported. Most patients with pulmonary involvement in HES improve with currently available therapies.",
keywords = "Asthma, Eosinophilic lung disease, Interstitial lung disease",
author = "{Dulohery Scrodin}, Megan and Patel, {Rajesh R.} and Frank Schneider and Ryu, {Jay H}",
year = "2011",
month = "1",
doi = "10.1016/j.rmed.2010.09.011",
language = "English (US)",
volume = "105",
pages = "114--121",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Lung involvement in hypereosinophilic syndromes

AU - Dulohery Scrodin, Megan

AU - Patel, Rajesh R.

AU - Schneider, Frank

AU - Ryu, Jay H

PY - 2011/1

Y1 - 2011/1

N2 - Background: Hypereosinophilic syndromes (HES) are a heterogeneous group of conditions that are characterized by tissue-associated eosinophilic inflammation and peripheral eosinophilia. Although clinical and radiologic features associated with most forms of eosinophilic lung diseases are relatively well-described, there is little known regarding lung involvement in HES. The aims of the present study were to ascertain the frequency of pulmonary involvement in HES and define associated clinical and radiologic features. Methods: We included all patients with HES seen over a 5-year period from 2004 to 2008 and examined their medical records and radiologic studies to obtain relevant data. Results: There were 49 patients (25 males and 24 females) with a median age of 50 years (range, 12-88 years); 18 (37%) had a history of tobacco use. In 12 patients (24%), these pulmonary manifestations were attributable to parenchymal lung involvement with HES. Radiologic manifestations of pulmonary involvement varied but most commonly consisted of patchy ground-glass opacities and consolidation; one patient exhibited numerous pulmonary nodules. Thirteen patients (27%) had asthma including 6 with a new diagnosis of this disorder. Initial treatment usually consisted of corticosteroids but additional therapeutic agents were employed during the clinical course and included hydroxyurea, interferon-α, imatinib, and mepolizumab. Most patients with pulmonary involvement with HES improved and no deaths were observed. Conclusion: One-quarter of HES patients manifested pulmonary involvement with variable radiologic findings. Asthma was more common in HES than previously reported. Most patients with pulmonary involvement in HES improve with currently available therapies.

AB - Background: Hypereosinophilic syndromes (HES) are a heterogeneous group of conditions that are characterized by tissue-associated eosinophilic inflammation and peripheral eosinophilia. Although clinical and radiologic features associated with most forms of eosinophilic lung diseases are relatively well-described, there is little known regarding lung involvement in HES. The aims of the present study were to ascertain the frequency of pulmonary involvement in HES and define associated clinical and radiologic features. Methods: We included all patients with HES seen over a 5-year period from 2004 to 2008 and examined their medical records and radiologic studies to obtain relevant data. Results: There were 49 patients (25 males and 24 females) with a median age of 50 years (range, 12-88 years); 18 (37%) had a history of tobacco use. In 12 patients (24%), these pulmonary manifestations were attributable to parenchymal lung involvement with HES. Radiologic manifestations of pulmonary involvement varied but most commonly consisted of patchy ground-glass opacities and consolidation; one patient exhibited numerous pulmonary nodules. Thirteen patients (27%) had asthma including 6 with a new diagnosis of this disorder. Initial treatment usually consisted of corticosteroids but additional therapeutic agents were employed during the clinical course and included hydroxyurea, interferon-α, imatinib, and mepolizumab. Most patients with pulmonary involvement with HES improved and no deaths were observed. Conclusion: One-quarter of HES patients manifested pulmonary involvement with variable radiologic findings. Asthma was more common in HES than previously reported. Most patients with pulmonary involvement in HES improve with currently available therapies.

KW - Asthma

KW - Eosinophilic lung disease

KW - Interstitial lung disease

UR - http://www.scopus.com/inward/record.url?scp=78649921086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649921086&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2010.09.011

DO - 10.1016/j.rmed.2010.09.011

M3 - Article

VL - 105

SP - 114

EP - 121

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 1

ER -